FDA Seems Set To Label Eylea For Retinopathy Of Prematurity Despite Failed Primary Endpoint

 
• By Brenda Sandburg
  
Premature infant
FDA panel to consider labeling of Eylea for treatment of retinopathy of prematurity in preterm infants. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers